CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $889 | $0 | $865 | $35,000 |
| % Growth | – | -100% | -97.5% | – |
| Cost of Goods Sold | $64,693 | $45,153 | $57,509 | $0 |
| Gross Profit | -$63,804 | -$45,153 | -$56,644 | $35,000 |
| % Margin | -7,177.1% | – | -6,548.4% | 100% |
| R&D Expenses | $58,902 | $166,147 | $72,484 | $82,155 |
| G&A Expenses | $16,931 | $18,916 | $19,296 | $18,124 |
| SG&A Expenses | $16,931 | $18,916 | $19,296 | $18,124 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7,578 | -$892 | $0 | -$691 |
| Operating Expenses | $68,255 | $184,171 | $91,780 | $99,588 |
| Operating Income | -$132,059 | -$229,324 | -$148,424 | -$64,588 |
| % Margin | -14,854.8% | – | -17,158.8% | -184.5% |
| Other Income/Exp. Net | $26,237 | $22,067 | $13,537 | $27,977 |
| Pre-Tax Income | -$105,822 | -$207,257 | -$134,887 | -$36,611 |
| Tax Expense | $619 | $1,292 | $1,109 | $700 |
| Net Income | -$106,441 | -$208,549 | -$135,996 | -$37,311 |
| % Margin | -11,973.1% | – | -15,722.1% | -106.6% |
| EPS | -1.17 | -2.4 | -1.58 | -0.44 |
| % Growth | 51.3% | -51.9% | -259.1% | – |
| EPS Diluted | -1.17 | -2.4 | -1.58 | -0.44 |
| Weighted Avg Shares Out | 91,305 | 87,070 | 85,939 | 85,464 |
| Weighted Avg Shares Out Dil | 91,305 | 87,070 | 85,939 | 85,464 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4,433 | $4,649 | $4,736 | $4,842 |
| EBITDA | -$101,389 | -$224,675 | -$143,688 | -$59,746 |
| % Margin | -11,404.8% | – | -16,611.3% | -170.7% |